Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain

Core Insights - Xenon Pharmaceuticals Inc. is hosting an investor webinar on October 6, 2025, to discuss its early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain [1][2]. Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company engaged in drug discovery, clinical development, and commercialization of therapeutics for patients in need [4]. - The company's lead molecule, azetukalner, is a selective Kv7 potassium channel opener currently in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD) [4]. - Xenon is also advancing a portfolio of potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for pain treatment [4]. Webinar Details - The webinar will take place from 11:30 AM to 12:30 PM Eastern Time, and participants can submit questions via chat or email [2]. - A live webcast will be available on the "Investors" section of Xenon's website, with a replay posted after the event [3].